Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series.

ABSTRACT:

Importance

Given the possible treatment modalities in psoriasis management, little is known about whether drug monitoring is associated with response rate.

Objective

To determine whether drug monitoring is associated with response to brodalumab therapy.

Design

A multicenter case series study of patients with psoriasis treated with brodalumab whose treatment with previous IL-17A inhibitor therapy failed. Patients were recruited from the Departments of Dermatology at Gentofte and Aarhus University Hospitals, Denmark, between 2018 and 2020. Patient visits were conducted after 4 and 12 weeks of therapy. Patients not achieving Psoriasis Area and Severity Index 75% improvement from baseline (PASI 75) after 12 weeks were discontinued and considered nonresponders. Patients ma

SUBMITTER: Enevold C 

PROVIDER: S-EPMC9161115 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature